Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by stanleyon Jan 11, 2012 7:43pm
353 Views
Post# 19393994

Brigus News, High grade results in zone 147

Brigus News, High grade results in zone 147

Josameyer:

Great call on the timing of the NR. John Embry continues to "out" the liars and cheats (central bankers) allegedly manipulating the POG & Silver.

https://www.sprott.com/Docs/InvestorsDigest/2011/MPLID_123011_pg461Emb.pdf

FOr those looking to get another perspective on why bullion and gold stocks are being manipulated. He also explains the strange trading patterns of GOLD & SIlver bullion & gold shares.

See also the McEwan Bloomberg interview on the Yahoo board.

BWDIK? How many excellent NR`s were met with market ìndifference"? In the interest of fairness, a company with a single source of production, unproven management team, tough geology, etc. Which is why a line in the NR missed an opportunity to highlight production diversification instead of mill feed. Meaning great drill results are not the issue in PPS appreciation in this market; when it continues to have a high trades to shares ratio.

Cheers

Stanley

Bullboard Posts